
Regeneron swoops on genetic testing firm 23andMe
DNA testing company 23andMe looks destined to be taken over by a pharma company, as Regeneron agrees a $256 million acquisition deal.
Newsletters and Deep Dive digital magazine
DNA testing company 23andMe looks destined to be taken over by a pharma company, as Regeneron agrees a $256 million acquisition deal.
The revitalisation of GSK's blood cancer therapy Blenrep continues with a second approval, in Japan, as a second-line treatment for multiple myeloma.
The FDA has granted full approval to Novavax's COVID-19 vaccine after a delay, but has limited its use.
The FDA has approved the first blood test for Alzheimer's disease based on a blood test – from Fujirebio – in a step forward for early diagnosis.
Novo Nordisk's chief executive Lars Fruergaard Jørgensen is stepping down by "mutual agreement" with the company's board.
Editor's Picks
Newsletters and Deep Dive
digital magazine
Editor's Picks